Table 1.
Subsequent therapy.
| ERd (n = 321) | Rd (n = 325) | |
|---|---|---|
| Any subsequent therapy | 192 (60) | 213 (66) |
| Most common subsequent therapya | ||
| Dexamethasone | 170 (53) | 178 (55) |
| Bortezomib | 122 (38) | 137 (42) |
| Cyclophosphamide | 96 (30) | 99 (30) |
| Pomalidomide | 82 (26) | 94 (29) |
| Lenalidomide | 57 (18) | 71 (22) |
| Carfilzomib | 47 (15) | 45 (14) |
| Melphalan | 32 (10) | 35 (11) |
| Bendamustine | 30 (9) | 27 (8) |
| Thalidomide | 30 (9) | 42 (13) |
| Daratumumab | 28 (9) | 38 (12) |
| Doxorubicin | 19 (6) | 29 (9) |
| Etoposide | 16 (5) | 17 (5) |
| Prednisolone | 16 (5) | 14 (4) |
| Prednisone | 15 (5) | 25 (8) |
| Cisplatin | 15 (5) | 15 (5) |
Data are n (%).
ERd elotuzumab plus lenalidomide and dexamethasone, Rd lenalidomide and dexamethasone.
a≥5% of patients in the ERd arm.